Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Exploratory Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Adults With Childhood Onset Fluency Disorder (Stuttering)

NCT04492956 is registered in ClinicalTrials.gov with Emalex Biosciences Inc. as lead sponsor.

NCT NCT04492956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04492956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Exploratory Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Adults With Childhood Onset Fluency Disorder (Stuttering)
Lead sponsor
Emalex Biosciences Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 22, 2020
Completion date
April 4, 2022
Enrollment
68 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

childhood-onset fluency disorder (stuttering)